Home-Based Administration of depo-subQ provera 104™ in the Uniject™ Injection System

This literature review details the key findings on the feasibility and acceptability of home delivery of depo-subQ provera 104™ in the Uniject™ injection system  (depo-subQ in Uniject). The review focused on self-injection and looked specifically at subcutaneous depot medroxyprogesterone acetate (DMPA) compared to the intramuscular formulation; considerations for home administration of injectable contraception, particularly in low-resource settings; and identified research needs for home administration, including self-injection, of depo-subQ in Uniject. A six-page briefing summary of this review is also available.

Publication date: July 2011

Available materials

    1. Home-Based Administration of depo-subQ provera 104™ in the Uniject™ Injection System (literature review) 1.2 MB PDF
      Hard copies are not available.
    2. Home-Based Administration of depo-subQ in the Uniject Injection System (briefing summary) 1.5 MB PDF
      Hard copies are not available.